UA70277C2 - Formulation of vasodilator agent for modulating seformulation of vasodilator agent for modulating sexual response on demand (variants) xual response on demand (variants) - Google Patents

Formulation of vasodilator agent for modulating seformulation of vasodilator agent for modulating sexual response on demand (variants) xual response on demand (variants) Download PDF

Info

Publication number: UA70277C2
Authority: UA; Ukraine
Prior art keywords: phentolamine; composition; vasodilator; hydrochloride; mesylate
Prior art date: 1995-04-28

Application number

UA97105248A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-28

Filing date

1996-04-26

Publication date

2004-10-15

1996-04-26 Application filed filed Critical

2004-10-15 Publication of UA70277C2 publication Critical patent/UA70277C2/uk

Links

239000000203 mixture Substances 0.000 title claims abstract description 64
239000003071 vasodilator agent Substances 0.000 title claims abstract description 54
230000036332 sexual response Effects 0.000 title claims abstract description 27
238000009472 formulation Methods 0.000 title abstract description 39
230000004044 response Effects 0.000 title description 23
230000017531 blood circulation Effects 0.000 claims abstract description 17
229960001999 phentolamine Drugs 0.000 claims description 43
PPWLAQVKIFDULF-UHFFFAOYSA-N 2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C=C1C1=CC=CC=C1 PPWLAQVKIFDULF-UHFFFAOYSA-N 0.000 claims description 42
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical group C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 claims description 42
229960003056 phentolamine mesylate Drugs 0.000 claims description 42
239000003826 tablet Substances 0.000 claims description 38
229940124549 vasodilator Drugs 0.000 claims description 34
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims description 20
210000004392 genitalia Anatomy 0.000 claims description 16
229930008281 A03AD01 - Papaverine Natural products 0.000 claims description 10
229960001789 papaverine Drugs 0.000 claims description 10
QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 claims description 9
229960003418 phenoxybenzamine Drugs 0.000 claims description 9
-1 naphthydrofuryl Chemical compound 0.000 claims description 8
239000000843 powder Substances 0.000 claims description 8
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 7
BMUKKTUHUDJSNZ-UHFFFAOYSA-N 4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)COC1=CC=CC=C1 BMUKKTUHUDJSNZ-UHFFFAOYSA-N 0.000 claims description 7
VRYMTAVOXVTQEF-UHFFFAOYSA-N acetic acid [4-[2-(dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] ester Chemical compound CC(C)C1=CC(OC(C)=O)=C(C)C=C1OCCN(C)C VRYMTAVOXVTQEF-UHFFFAOYSA-N 0.000 claims description 7
239000007910 chewable tablet Substances 0.000 claims description 7
229960004801 imipramine Drugs 0.000 claims description 7
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 7
229960004819 isoxsuprine Drugs 0.000 claims description 7
229960003509 moxisylyte Drugs 0.000 claims description 7
229960001722 verapamil Drugs 0.000 claims description 7
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 6
239000000006 Nitroglycerin Substances 0.000 claims description 6
229960003711 glyceryl trinitrate Drugs 0.000 claims description 6
229960002312 tolazoline Drugs 0.000 claims description 6
JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 claims description 6
229940068682 chewable tablet Drugs 0.000 claims description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 3
239000002775 capsule Substances 0.000 claims description 3
229960002715 nicotine Drugs 0.000 claims description 3
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
239000000725 suspension Substances 0.000 claims description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 2
239000007911 effervescent powder Substances 0.000 claims 1
239000007938 effervescent tablet Substances 0.000 claims 1
239000007788 liquid Substances 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
238000000034 method Methods 0.000 abstract description 32
241000282414 Homo sapiens Species 0.000 abstract description 5
201000001881 impotence Diseases 0.000 description 29
230000001856 erectile effect Effects 0.000 description 23
210000001367 artery Anatomy 0.000 description 18
229940079593 drug Drugs 0.000 description 16
239000003814 drug Substances 0.000 description 16
230000000694 effects Effects 0.000 description 15
230000001568 sexual effect Effects 0.000 description 15
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 12
210000003899 penis Anatomy 0.000 description 12
238000011282 treatment Methods 0.000 description 11
230000000638 stimulation Effects 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 9
239000000150 Sympathomimetic Substances 0.000 description 8
239000007924 injection Substances 0.000 description 8
238000002347 injection Methods 0.000 description 8
210000001215 vagina Anatomy 0.000 description 8
239000002550 vasoactive agent Substances 0.000 description 8
230000001965 increasing effect Effects 0.000 description 7
210000002381 plasma Anatomy 0.000 description 7
239000000243 solution Substances 0.000 description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
238000004090 dissolution Methods 0.000 description 6
239000007926 intracavernous injection Substances 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
230000002792 vascular Effects 0.000 description 6
230000000304 vasodilatating effect Effects 0.000 description 6
208000010228 Erectile Dysfunction Diseases 0.000 description 5
BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 5
230000037007 arousal Effects 0.000 description 5
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 5
210000003029 clitoris Anatomy 0.000 description 5
239000007884 disintegrant Substances 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
229940068196 placebo Drugs 0.000 description 5
239000000902 placebo Substances 0.000 description 5
238000013139 quantization Methods 0.000 description 5
229960000317 yohimbine Drugs 0.000 description 5
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 5
AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 5
MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
210000005225 erectile tissue Anatomy 0.000 description 4
210000003090 iliac artery Anatomy 0.000 description 4
230000006872 improvement Effects 0.000 description 4
229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 4
210000002460 smooth muscle Anatomy 0.000 description 4
239000007787 solid Substances 0.000 description 4
PTGXAUBQBSGPKF-UHFFFAOYSA-N 4-[1-hydroxy-2-(4-phenylbutan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)CCC1=CC=CC=C1 PTGXAUBQBSGPKF-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000000674 adrenergic antagonist Substances 0.000 description 3
229960003455 buphenine Drugs 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000002124 endocrine Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
239000007937 lozenge Substances 0.000 description 3
239000002674 ointment Substances 0.000 description 3
239000006187 pill Substances 0.000 description 3
239000000050 smooth muscle relaxant Substances 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000007916 tablet composition Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
206010058359 Hypogonadism Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000002160 alpha blocker Substances 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
HSNWZBCBUUSSQD-UHFFFAOYSA-N amyl nitrate Chemical compound CCCCCO[N+]([O-])=O HSNWZBCBUUSSQD-UHFFFAOYSA-N 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000008602 contraction Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000009986 erectile function Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
230000003176 fibrotic effect Effects 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
238000005461 lubrication Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
229960003512 nicotinic acid Drugs 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
210000002445 nipple Anatomy 0.000 description 2
229960003207 papaverine hydrochloride Drugs 0.000 description 2
230000035515 penetration Effects 0.000 description 2
229940023488 pill Drugs 0.000 description 2
238000003825 pressing Methods 0.000 description 2
230000033904 relaxation of vascular smooth muscle Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000035807 sensation Effects 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000001975 sympathomimetic effect Effects 0.000 description 2
238000001931 thermography Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000008733 trauma Effects 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
230000002227 vasoactive effect Effects 0.000 description 2
UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
NKQVYJRZBVRXRU-UHFFFAOYSA-N 2-methyl-2-(methylamino)propanenitrile Chemical compound CNC(C)(C)C#N NKQVYJRZBVRXRU-UHFFFAOYSA-N 0.000 description 1
BPQZYOJIXDMZSX-UHFFFAOYSA-N 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethylpropan-1-amine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21.C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 BPQZYOJIXDMZSX-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
208000034656 Contusions Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
244000303965 Cyamopsis psoralioides Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
208000021663 Female sexual arousal disease Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
239000005913 Maltodextrin Substances 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010056303 Painful erection Diseases 0.000 description 1
206010033892 Paraplegia Diseases 0.000 description 1
208000004362 Penile Induration Diseases 0.000 description 1
208000020758 Peyronie disease Diseases 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
201000005746 Pituitary adenoma Diseases 0.000 description 1
206010061538 Pituitary tumour benign Diseases 0.000 description 1
208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
208000020339 Spinal injury Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
RHTNTTODYGNRSP-UHFFFAOYSA-N Tolazoline hydrochloride Chemical compound Cl.C=1C=CC=CC=1CC1=NCCN1 RHTNTTODYGNRSP-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
239000000464 adrenergic agent Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000003420 antiserotonin agent Substances 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
210000003403 autonomic nervous system Anatomy 0.000 description 1
210000001142 back Anatomy 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229940030611 beta-adrenergic blocking agent Drugs 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000009084 cardiovascular function Effects 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
230000006378 damage Effects 0.000 description 1
108700027018 deaminooxytocin Proteins 0.000 description 1
GTYWGUNQAMYZPF-QPLNMOKZSA-N demoxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 GTYWGUNQAMYZPF-QPLNMOKZSA-N 0.000 description 1
229960000477 demoxytocin Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000003777 experimental drug Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000001752 female genitalia Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
210000003953 foreskin Anatomy 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
PIPZGJSEDRMUAW-VJDCAHTMSA-N hydron;methyl (1s,15r,18s,19r,20s)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate;chloride Chemical compound Cl.C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 PIPZGJSEDRMUAW-VJDCAHTMSA-N 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
230000002989 hypothyroidism Effects 0.000 description 1
208000003532 hypothyroidism Diseases 0.000 description 1
XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
229960002102 imipramine hydrochloride Drugs 0.000 description 1
229960000375 imipramine pamoate Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960004164 isoxsuprine hydrochloride Drugs 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000005976 liver dysfunction Effects 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
210000000260 male genitalia Anatomy 0.000 description 1
229940035034 maltodextrin Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
230000001272 neurogenic effect Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
PLXPTFQGYWXIEA-UHFFFAOYSA-N nitroformonitrile Chemical compound [O-][N+](=O)C#N PLXPTFQGYWXIEA-UHFFFAOYSA-N 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
208000021310 pituitary gland adenoma Diseases 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
201000011264 priapism Diseases 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011471 prostatectomy Methods 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
210000002176 pterygoid muscle Anatomy 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
229940023144 sodium glycolate Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
210000003478 temporal lobe Anatomy 0.000 description 1
229960002649 tolazoline hydrochloride Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000004218 vascular function Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000000827 velocimetry Methods 0.000 description 1
229960000881 verapamil hydrochloride Drugs 0.000 description 1
239000004520 water soluble gel Substances 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1
229960000949 yohimbine hydrochloride Drugs 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Gynecology & Obstetrics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Medicines Containing Plant Substances (AREA)

UA97105248A 1995-04-28 1996-04-26 Formulation of vasodilator agent for modulating seformulation of vasodilator agent for modulating sexual response on demand (variants) xual response on demand (variants) UA70277C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/431,145 US5731339A (en)	1995-04-28	1995-04-28	Methods and formulations for modulating the human sexual response
PCT/US1996/005816 WO1996033705A1 (en)	1995-04-28	1996-04-26	Methods and formulations for modulating the human sexual response

Publications (1)

Publication Number	Publication Date
UA70277C2 true UA70277C2 (en)	2004-10-15

Family

ID=23710676

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA97105248A UA70277C2 (en)	1995-04-28	1996-04-26	Formulation of vasodilator agent for modulating seformulation of vasodilator agent for modulating sexual response on demand (variants) xual response on demand (variants)

Country Status (35)

Country	Link
US (6)	US5731339A (is)
EP (2)	EP0962225A3 (is)
JP (2)	JP3469901B2 (is)
KR (1)	KR100363056B1 (is)
CN (1)	CN101816638A (is)
AR (1)	AR001739A1 (is)
AT (1)	ATE185695T1 (is)
AU (1)	AU710111B2 (is)
BG (1)	BG63071B1 (is)
BR (1)	BR9604983A (is)
CA (1)	CA2219502C (is)
CZ (1)	CZ294350B6 (is)
DE (1)	DE69604762T2 (is)
DK (1)	DK0767660T3 (is)
EE (1)	EE03472B1 (is)
ES (1)	ES2140847T3 (is)
GR (1)	GR3032182T3 (is)
HU (1)	HU222044B1 (is)
IL (1)	IL117871A (is)
IS (1)	IS4598A (is)
LT (1)	LT4404B (is)
LV (1)	LV12038B (is)
MD (1)	MD1663C2 (is)
NO (1)	NO314746B1 (is)
NZ (1)	NZ307020A (is)
PL (1)	PL185528B1 (is)
PT (1)	PT767660E (is)
RO (1)	RO116866B1 (is)
RU (2)	RU2177786C2 (is)
SI (1)	SI9620058A (is)
SK (1)	SK283847B6 (is)
TR (2)	TR199701260T1 (is)
UA (1)	UA70277C2 (is)
WO (1)	WO1996033705A1 (is)
ZA (1)	ZA963380B (is)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5731339A (en) *	1995-04-28	1998-03-24	Zonagen, Inc.	Methods and formulations for modulating the human sexual response
US6036977A (en) *	1995-09-29	2000-03-14	L.A.M. Pharmaceutical Corp.	Drug preparations for treating sexual dysfunction
US6251436B1 (en)	1995-09-29	2001-06-26	L.A.M. Pharmaceutical Corporation	Drug preparations for treating sexual dysfunction
US6387407B1 (en)	1995-09-29	2002-05-14	L.A.M. Pharmaceutical Corporation	Topical drug preparations
US5897880A (en)	1995-09-29	1999-04-27	Lam Pharmaceuticals, Llc.	Topical drug preparations
US6258032B1 (en) *	1997-01-29	2001-07-10	William M. Hammesfahr	Method of diagnosis and treatment and related compositions and apparatus
US20020143007A1 (en) *	1996-02-02	2002-10-03	Garvey David S.	Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US6294517B1 (en)	1996-02-02	2001-09-25	Nitromed, Inc.	Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US6469065B1 (en)	1996-02-02	2002-10-22	Nitromed, Inc.	Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US20050065161A1 (en) *	1996-02-02	2005-03-24	Nitromed, Inc.	Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6323211B1 (en) *	1996-02-02	2001-11-27	Nitromed, Inc.	Compositions and methods for treating sexual dysfunctions
US5958926A (en) *	1996-11-01	1999-09-28	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en)	1996-11-01	2001-06-19	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US6331543B1 (en) *	1996-11-01	2001-12-18	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
GR1002847B (el)	1997-05-06	1998-01-27		Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
NZ500921A (en) *	1997-05-19	2002-11-26	Zonagen Inc	Composition containing a-adrenergic antagonist and a phosphodiesterase inhibitor or a dopaminergic agonist for modulating the human sexual response
US20030004170A1 (en) *	1997-05-19	2003-01-02	Zonagen, Inc.	Combination therapy for modulating the human sexual response
WO1998058633A2 (en)	1997-06-23	1998-12-30	Queen's University At Kingston	Microdose therapy of vascular conditions by no donors
KR20010021625A (ko)	1997-07-09	2001-03-15	추후보정	개선된 남성발기 기능장애 치료방법 및 그 조성물
US6103765A (en)	1997-07-09	2000-08-15	Androsolutions, Inc.	Methods for treating male erectile dysfunction
US6399618B1 (en)	1997-07-09	2002-06-04	Cardiome Pharma Corp	Compositions and methods for modulating sexual activity
US5947901A (en)	1997-09-09	1999-09-07	Redano; Richard T.	Method for hemodynamic stimulation and monitoring
US6593369B2 (en)	1997-10-20	2003-07-15	Vivus, Inc.	Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US20050070516A1 (en) *	1997-10-28	2005-03-31	Vivus Inc.	As-needed administration of an androgenic agent to enhance female desire and responsiveness
JP2001520999A (ja)	1997-10-28	2001-11-06	アシビ，エルエルシー	女性の性的機能不全の処置
US5877216A (en) *	1997-10-28	1999-03-02	Vivus, Incorporated	Treatment of female sexual dysfunction
US6472425B1 (en)	1997-10-31	2002-10-29	Nitromed, Inc.	Methods for treating female sexual dysfunctions
TW380045B (en)	1998-01-13	2000-01-21	Urometrics Inc	Devices and methods for monitoring female arousal
FR2774593B1 (fr) *	1998-02-12	2000-05-05	Philippe Gorny	Obtention d'un medicament destine a combattre les dysfonctions sexuelles feminines
WO1999059584A1 (en) *	1998-05-20	1999-11-25	Schering Corporation	Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
US6011043A (en) *	1998-06-19	2000-01-04	Schering Corporation	Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6031005A (en) *	1998-08-03	2000-02-29	Easterling; W. Jerry	Composition and method for treating Peyronie's disease and related connective tissue disorders
US6525100B1 (en)	1998-08-03	2003-02-25	W. Jerry Easterling	Composition and method for treating peyronie's disease and related fibrotic tissue disorders
US20040170675A1 (en) *	1998-08-03	2004-09-02	Easterling W. Jerry	Noninvasive method for treating cellulite through transdermal delivery of calcium channel blocker agents and medicament for use in such method
US6627663B2 (en)	1998-08-03	2003-09-30	W. Jerry Easterling	Noninvasive method for treating hemangiomas through transdermal delivery of calcium channel blocker agents and medicament for use in such method
GR1003199B (el) *	1998-08-14	1999-09-01		Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
US6284763B1 (en) *	1998-08-26	2001-09-04	Queen's University At Kingston	Methods for remodeling neuronal and cardiovascular pathways
US6482426B1 (en) *	1998-09-17	2002-11-19	Zonagen, Inc.	Compositions for the treatment of male erectile dysfunction
US6706682B2 (en) *	1999-01-21	2004-03-16	The Trustees Of Columbia University In The City Of New York	Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
US6552024B1 (en)	1999-01-21	2003-04-22	Lavipharm Laboratories Inc.	Compositions and methods for mucosal delivery
AU3724400A (en) *	1999-03-08	2000-09-28	Merck & Co., Inc.	Methods and compositions for treating erectile dysfunction
KR20020015310A (ko) *	1999-04-06	2002-02-27	로버트 엘. 로브	신체적인 성적반응을 변화시키는 방법
US6613768B1 (en)	1999-04-30	2003-09-02	Lilly Icos Llc	Treatment of female arousal disorder
IT1312310B1 (it)	1999-05-07	2002-04-15	Recordati Ind Chimica E Farma	Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
US20010003120A1 (en) *	1999-05-14	2001-06-07	M. D. Robert Hines	Method for treating erectile dysfunction
US6916845B2 (en) *	1999-06-17	2005-07-12	Zhongcheng Xin	Method for prevention and treatment of male and female sexual dysfunction
US6730065B1 (en) *	2000-09-15	2004-05-04	Ocularis Pharma, Inc.	Night vision composition
US6399591B1 (en) *	2000-01-19	2002-06-04	Yung-Shin Pharmaceutical Ind. Co., Ltd.	Chargeable pharmaceutical tablets
US6730691B1 (en)	2000-02-10	2004-05-04	Miles A. Galin	Uses of alpha adrenergic blocking agents
PT1280531E (pt) *	2000-05-12	2007-02-28	Novalar Pharmaceuticals Inc	Formulação consistindo de mesilato de fentolamina e sua utilização
DE60130007T2 (de) *	2000-06-27	2008-04-30	Qualilife Pharmaceuticals Inc.	Zusammensetzungen und verfahren zur behandlung der weiblichen sexuellen reaktion
BRPI0003386B8 (pt) *	2000-08-08	2021-05-25	Cristalia Produtos Quim Farmaceuticos Ltda	pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
US6503894B1 (en) *	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) *	2000-08-30	2004-05-13	Dudley Robert E.	Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) *	2000-08-30	2004-01-01	Dudley Robert E.	Androgen pharmaceutical composition and method for treating depression
KR20020020536A (ko) *	2000-09-09	2002-03-15	장우영	발기유발제
US6821978B2 (en)	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
US20060211753A1 (en) *	2000-11-03	2006-09-21	Ocularis Pharma, Inc.	Method and composition which reduces stimulation of muscles which dilate the eye
US20020107230A1 (en) *	2000-12-22	2002-08-08	Waldon R. Forrest	Methods and formulations for the treatment of female sexual dysfunction
MXPA03007960A (es)	2001-03-06	2003-12-04	Cellegy Pharma Inc	Compuestos y metodos para el tratamiento de desordenes urogenitales.
US20020172712A1 (en) *	2001-03-19	2002-11-21	Alan Drizen	Antiemetic, anti-motion sustained release drug delivery system
US20030138494A1 (en) *	2001-05-15	2003-07-24	L.A.M. Pharmaceutical Corporation	Drug preparations for treating sexual dysfunction
CA2457433A1 (en)	2001-08-10	2003-02-20	Molecular Design International Inc.	Novel alpha adrenergic agents
DE60226615D1 (is) *	2001-08-28	2008-06-26	Schering Corp
GB0130704D0 (en) *	2001-12-21	2002-02-06	Glaxo Group Ltd	New use
US8133903B2 (en) *	2003-10-21	2012-03-13	Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center	Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
WO2004037183A2 (en) *	2002-10-22	2004-05-06	Harbor-Ucla Research And Education Institute	Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases
RU2228754C1 (ru) *	2003-06-19	2004-05-20	Сегал Александр Самуилович	Способ лечения и профилактики эректильной дисфункции
US7390503B1 (en)	2003-08-22	2008-06-24	Barr Laboratories, Inc.	Ondansetron orally disintegrating tablets
CN100336506C (zh) *	2004-04-23	2007-09-12	北京科信必成医药科技发展有限公司	甲磺酸酚妥拉明口腔崩解片及其制备方法
KR101292492B1 (ko)	2004-05-11	2013-08-01	이모셔널 브레인 비.브이.	약제학적 제형물 및 여성 성기능 부전의 치료에서 그것의용도
CA2568640C (en)	2004-06-04	2011-08-09	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition containing irbesartan
US20060052402A1 (en) *	2004-09-08	2006-03-09	Woodward John R	Method of female sexual enhancement
US20080119445A1 (en) *	2004-09-08	2008-05-22	Woodward John R	Methods of female sexual enhancement
US20060252734A1 (en) *	2004-09-08	2006-11-09	Woodward John R	Methods of female sexual enhancement
US20060276442A1 (en) *	2004-09-08	2006-12-07	Woodward John R	Methods of female sexual enhancement
US20060167022A1 (en) *	2004-09-08	2006-07-27	Woodward John R	Method of female sexual enhancement
DK1802277T3 (da) *	2004-10-18	2010-05-17	Polymun Scient Immunbio Forsch	Liposomal sammensætning indeholdende en aktiv bestanddel til relaksation af glat muskulatur og terapeutisk anvendelse af sammensætningen
CA2601773A1 (en) *	2005-02-03	2006-08-10	Duramed Pharmaceuticals, Inc.	Compositions of unconjugated estrogens and methods for their use
US20070088012A1 (en) *	2005-04-08	2007-04-19	Woun Seo	Method of treating or preventing type-2 diabetes
TR201815853T4 (tr)	2005-10-12	2018-11-21	Besins Healthcare Sarl	Hipogonadizmin tedavisinde kullanıma yönelik geliştirilmiş testosteron jeli.
EP1790343A1 (en)	2005-11-11	2007-05-30	Emotional Brain B.V.	Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) *	2006-11-03	2008-05-28	Emotional Brain B.V.	Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2008151204A1 (en)	2007-06-04	2008-12-11	Sequent Medical Inc.	Methods and devices for treatment of vascular defects
SG10201704221XA (en)	2012-12-05	2017-06-29	Ge Nutrients Inc	Use of fenugreek extract to enhance female libido
US9089560B2 (en)	2013-02-01	2015-07-28	Ocularis Pharma, Llc	Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
WO2014121027A1 (en)	2013-02-01	2014-08-07	Oculars Pharma, Llc	Aqueous ophthalmic solutions of phentolamine and medical uses thereof
CN104013588A (zh) *	2014-04-14	2014-09-03	杨荣辰	一种甲磺酸酚妥拉明分散片及其制备方法
WO2016167254A1 (ja) *	2015-04-17	2016-10-20	株式会社山田養蜂場本社	蜂の子を含有する滋養強壮剤
WO2017100324A1 (en) *	2015-12-10	2017-06-15	Repros Therapeutics Inc.	Combination therapy for treating female hypoactive sexual desire disorders
WO2017168174A1 (en)	2016-04-02	2017-10-05	N4 Pharma Uk Limited	New pharmaceutical forms of sildenafil
US12161629B2 (en)	2018-10-15	2024-12-10	Opus Genetics, Inc.	Methods and compositions for treatment of glaucoma and related conditions
JP7670945B2 (ja)	2018-10-26	2025-05-01	オーパス・ジェネティクス・インコーポレイテッド	老眼、散瞳、および他の眼障害の治療のための方法および組成物
CN115368310B (zh)	2021-05-18	2025-06-27	奥库菲尔医药公司	合成甲磺酸酚妥拉明的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2503059A (en) *		1950-04-04		Nxchj
US3937834A (en) *	1970-10-02	1976-02-10	Ciba-Geigy Corporation	Pharmaceutical preparations
US3943246A (en) *	1972-07-10	1976-03-09	Sandoz Ltd.	Organic compounds
US4139617A (en) *	1974-05-13	1979-02-13	Richardson-Merrell Inc.	19-Oxygenated-androst-5-enes for the enhancement of libido
GB1500300A (en) *	1975-01-06	1978-02-08	Ciba Geigy Ag	Pharmaceutical preparation for the treatment of circulatory disorders
NZ179623A (en) *	1975-01-06	1978-03-06	Ciba Geigy	Pharmaceutical preparation containing a beta-receptor blocking compound, a compound regulating thrombocyte function and optionally an alpha-receptor blocking compund
US4127118B1 (en) *	1977-03-16	1995-12-19	Alvaro Latorre	Method of effecting and enhancing an erection
EP0007572B1 (de) *	1978-07-21	1983-04-27	Ciba-Geigy Ag	Pharmazeutische Präparate mit einem Gehalt an einer Amantadin-Verbindung
US4521421A (en) *	1983-09-26	1985-06-04	Eli Lilly And Company	Treatment of sexual dysfunction
US4530920A (en) *	1983-11-07	1985-07-23	Syntex (U.S.A.) Inc.	Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
EP0152379A3 (de) *	1984-02-15	1986-10-29	Ciba-Geigy Ag	Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
US4885173A (en) *	1985-05-01	1989-12-05	University Of Utah	Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US4863911A (en) *	1986-08-04	1989-09-05	University Of Florida	Method for treating male sexual dysfunction
US4801587A (en) *	1987-03-02	1989-01-31	Gene Voss	Impotence ointment
US5256652A (en) *	1987-11-12	1993-10-26	Pharmedic Co.	Topical compositions and methods for treatment of male impotence
SE463851B (sv) *	1988-09-02	1991-02-04	Amsu Ltd	Komposition foer behandling av erektil dysfunktion via uretra
US5059603A (en) *	1989-06-12	1991-10-22	Centuries Laboratories, Inc.	Method and composition for treating impotence
US5065744A (en) *	1989-06-16	1991-11-19	Zusmanovsky Zinovy A	Device for treatment of sexual impotence in human males
FR2649613B1 (fr) *	1989-07-11	1991-09-27	Virag Ronald	Medicament vaso-actif
US5079018A (en) *	1989-08-14	1992-01-07	Neophore Technologies, Inc.	Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5236904A (en) *	1989-09-18	1993-08-17	Senetek, Plc	Erection-inducing methods and compositions
US5270323A (en) *	1990-05-31	1993-12-14	Pfizer Inc.	Method of treating impotence
US5399581A (en) *	1990-12-26	1995-03-21	Laragh; John H.	Method and compositions for treatment of sexual impotence
US5298261A (en) *	1992-04-20	1994-03-29	Oregon Freeze Dry, Inc.	Rapidly distintegrating tablet
US5565466A (en) *	1993-08-13	1996-10-15	Zonagen, Inc.	Methods for modulating the human sexual response
US5731339A (en) *	1995-04-28	1998-03-24	Zonagen, Inc.	Methods and formulations for modulating the human sexual response

1995
- 1995-04-28 US US08/431,145 patent/US5731339A/en not_active Expired - Lifetime
1996
- 1996-04-11 IL IL11787196A patent/IL117871A/xx not_active IP Right Cessation
- 1996-04-26 RU RU97119646/14A patent/RU2177786C2/ru active
- 1996-04-26 KR KR1019970707656A patent/KR100363056B1/ko not_active Expired - Lifetime
- 1996-04-26 EP EP99114470A patent/EP0962225A3/en not_active Withdrawn
- 1996-04-26 CA CA002219502A patent/CA2219502C/en not_active Expired - Lifetime
- 1996-04-26 TR TR97/01260T patent/TR199701260T1/xx unknown
- 1996-04-26 NZ NZ307020A patent/NZ307020A/xx not_active IP Right Cessation
- 1996-04-26 TR TR1999/01973T patent/TR199901973T2/xx unknown
- 1996-04-26 CZ CZ19973393A patent/CZ294350B6/cs not_active IP Right Cessation
- 1996-04-26 AT AT96913174T patent/ATE185695T1/de active
- 1996-04-26 PT PT96913174T patent/PT767660E/pt unknown
- 1996-04-26 SK SK1458-97A patent/SK283847B6/sk unknown
- 1996-04-26 CN CN200910151335A patent/CN101816638A/zh active Pending
- 1996-04-26 PL PL96323087A patent/PL185528B1/pl unknown
- 1996-04-26 AR AR33632696A patent/AR001739A1/es not_active Application Discontinuation
- 1996-04-26 BR BR9604983A patent/BR9604983A/pt not_active Application Discontinuation
- 1996-04-26 DE DE69604762T patent/DE69604762T2/de not_active Expired - Lifetime
- 1996-04-26 EP EP96913174A patent/EP0767660B1/en not_active Expired - Lifetime
- 1996-04-26 ES ES96913174T patent/ES2140847T3/es not_active Expired - Lifetime
- 1996-04-26 UA UA97105248A patent/UA70277C2/uk unknown
- 1996-04-26 AU AU55768/96A patent/AU710111B2/en not_active Expired
- 1996-04-26 WO PCT/US1996/005816 patent/WO1996033705A1/en not_active Ceased
- 1996-04-26 MD MD98-0007A patent/MD1663C2/ro unknown
- 1996-04-26 HU HU9802825A patent/HU222044B1/hu active IP Right Grant
- 1996-04-26 SI SI9620058A patent/SI9620058A/sl unknown
- 1996-04-26 DK DK96913174T patent/DK0767660T3/da active
- 1996-04-26 EE EE9700276A patent/EE03472B1/xx not_active IP Right Cessation
- 1996-04-26 RO RO97-01998A patent/RO116866B1/ro unknown
- 1996-04-26 JP JP53273896A patent/JP3469901B2/ja not_active Expired - Lifetime
- 1996-04-26 RU RU2000100756/15A patent/RU2239424C2/ru active
- 1996-04-29 ZA ZA963380A patent/ZA963380B/xx unknown
1997
- 1997-10-24 IS IS4598A patent/IS4598A/is unknown
- 1997-10-27 LV LVP-97-209A patent/LV12038B/en unknown
- 1997-10-27 NO NO19974965A patent/NO314746B1/no not_active IP Right Cessation
- 1997-10-28 LT LT97-168A patent/LT4404B/lt not_active IP Right Cessation
- 1997-10-29 US US08/959,672 patent/US5981563A/en not_active Expired - Lifetime
- 1997-10-31 BG BG102010A patent/BG63071B1/bg unknown
1998
- 1998-03-10 US US09/037,898 patent/US6100286A/en not_active Expired - Lifetime
1999
- 1999-07-28 US US09/362,486 patent/US6124337A/en not_active Expired - Lifetime
- 1999-07-28 US US09/362,825 patent/US6051594A/en not_active Expired - Lifetime
- 1999-07-28 US US09/362,518 patent/US6166061A/en not_active Expired - Lifetime
- 1999-12-17 GR GR990403268T patent/GR3032182T3/el unknown
2001
- 2001-07-16 JP JP2001215110A patent/JP4531301B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
GR3032182T3 (en)	2000-04-27
US5981563A (en)	1999-11-09
EP0962225A2 (en)	1999-12-08
BR9604983A (pt)	1999-06-15
JPH11504902A (ja)	1999-05-11
US6166061A (en)	2000-12-26
TR199901973T2 (xx)	1999-09-21
RO116866B1 (ro)	2001-07-30
SK145897A3 (en)	1998-06-03
RU2177786C2 (ru)	2002-01-10
PL323087A1 (en)	1998-03-02
NZ307020A (is)	1999-06-29
KR100363056B1 (ko)	2003-04-10
IL117871A0 (en)	1996-08-04
AU710111B2 (en)	1999-09-16
MD980007A (en)	1999-07-31
BG102010A (en)	1998-04-30
ES2140847T3 (es)	2000-03-01
LV12038A (lv)	1998-05-20
LV12038B (en)	1998-08-20
BG63071B1 (bg)	2001-03-30
NO974965D0 (no)	1997-10-27
ATE185695T1 (de)	1999-11-15
LT97168A (en)	1998-06-25
PL185528B1 (pl)	2003-05-30
HUP9802825A2 (hu)	1999-06-28
DE69604762T2 (de)	2000-03-09
US6100286A (en)	2000-08-08
SI9620058A (sl)	1998-06-30
JP4531301B2 (ja)	2010-08-25
AU5576896A (en)	1996-11-18
CN101816638A (zh)	2010-09-01
PT767660E (pt)	2000-04-28
NO974965L (no)	1997-12-23
CZ339397A3 (cs)	1998-03-18
EP0767660A1 (en)	1997-04-16
US5731339A (en)	1998-03-24
WO1996033705A1 (en)	1996-10-31
ZA963380B (en)	1996-11-08
JP3469901B2 (ja)	2003-11-25
IL117871A (en)	2001-01-11
MD1663C2 (ro)	2001-11-30
IS4598A (is)	1997-10-24
EE9700276A (et)	1998-04-15
LT4404B (lt)	1998-11-25
AR001739A1 (es)	1997-11-26
HU222044B1 (hu)	2003-04-28
TR199701260T1 (xx)	1998-03-21
CA2219502A1 (en)	1996-10-31
CA2219502C (en)	2002-11-19
DK0767660T3 (da)	2000-04-25
EE03472B1 (et)	2001-08-15
DE69604762D1 (de)	1999-11-25
US6124337A (en)	2000-09-26
EP0962225A3 (en)	2000-05-10
SK283847B6 (sk)	2004-03-02
US6051594A (en)	2000-04-18
CZ294350B6 (cs)	2004-12-15
EP0767660B1 (en)	1999-10-20
MD1663B2 (en)	2001-05-31
EP0767660A4 (en)	1997-08-27
JP2002087957A (ja)	2002-03-27
NO314746B1 (no)	2003-05-19
HUP9802825A3 (en)	2000-06-28
KR19990008131A (ko)	1999-01-25
RU2239424C2 (ru)	2004-11-10

Publication	Publication Date	Title
UA70277C2 (en)	2004-10-15	Formulation of vasodilator agent for modulating seformulation of vasodilator agent for modulating sexual response on demand (variants) xual response on demand (variants)
EP0714300B1 (en)	1998-12-23	Methods for modulating the human sexual response
JP2009280621A (ja)	2009-12-03	ヒトの性応答を調節するための組み合わせ治療
AU696815C (en)	1999-06-24	Methods for modulating the human sexual response
AU723242B2 (en)	2000-08-24	Methods for modulating the human sexual response
US20030207891A1 (en)	2003-11-06	Combination therapy for modulating the human sexual response
MXPA01010021A (es)	2002-07-30	Metodos para la modulacion de la respuesta sexual humana..